PBYI
Puma Biotechnology, Inc.
Biotechnology · Healthcare · United States
10.54
close · 2026-10-29
value
58
cheaper than peers58
quality
74
stronger fundamentals74
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 2.00× | 91 |
| EV to EBITDA | 8.31× | 64 |
| price to book | 3.89× | 44 |
| forward P/E | 30.11× | 28 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 21.6% | 88 |
| operating margin | -8.5% | 74 |
| debt to equity | 12.4% | 58 |
| revenue growth | -2.6% | 33 |
4 of 4 measures available
Facts
| market cap | $544M |
| free cash flow | $44.1M |
| employees | 179 |
| first trade | 2012-04-24 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | 0.61 | 0.62 | 0.45 | 0.00 | not reported |
| free cash flow | $41.7M | $38.9M | $14.4M | -$22.8M | not reported |
| net income | $31.1M | $30.3M | $21.6M | $2,000 | not reported |
| revenue | $228.4M | $230.5M | $235.6M | $228.0M | not reported |
| unusual items | not reported | $0 | -$625,000 | -$19.5M | -$17.7M |